AICAR

Origin and Structure

AICAR — 5-aminoimidazole-4-carboxamide ribonucleotide — is a nucleotide intermediate in the de novo purine biosynthesis pathway. Its orally bioavailable analogue acadesine (AICA riboside, the non-phosphorylated ribose form) has been the subject of clinical investigation since the 1980s. Like 5-amino-1MQ, AICAR is not a peptide: it is a small-molecule AMP mimetic with a molecular weight of 258 Da, included in the metabolic-wellness conversation because it activates the same master energy-sensing pathway that many exercise-mimetic peptides target.

Acadesine was initially developed as a cardioprotective agent for coronary artery bypass surgery, advancing through Phase 3 trials in the 1990s before failing to demonstrate a significant reduction in cardiac events. It was later repurposed in oncology trials for chronic lymphocytic leukemia and has been studied in several dozen academic clinical trials across varied indications.

Mechanism — AMPK Activation

AICAR is transported into cells and phosphorylated by adenosine kinase to form ZMP, an AMP analogue. ZMP mimics the allosteric effect of AMP on AMP-activated protein kinase (AMPK) — the cellular energy sensor that is activated when the AMP/ATP ratio rises during energy stress. Activated AMPK shifts cellular metabolism toward ATP-producing catabolic pathways and away from ATP-consuming anabolic ones:

• Increased fatty acid oxidation. Phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) lowers malonyl-CoA, releasing CPT-1 to shuttle fatty acids into mitochondria.
• Increased glucose uptake. GLUT4 translocation to skeletal muscle membrane increases, insulin-independently.
• Suppressed lipogenesis and cholesterogenesis. ACC and HMG-CoA reductase are both inhibited.
• Mitochondrial biogenesis. PGC-1α is activated, driving transcription of mitochondrial genes.

The 2008 paper by Narkar and colleagues in Cell ("AMPK and PPARδ agonists are exercise mimetics") was the publication that catapulted AICAR into the performance-enhancement conversation. In sedentary mice, four weeks of AICAR produced gene-expression changes and endurance improvements resembling those from endurance training.

Evidence Base

The AICAR/acadesine literature is unusual in being both deep (decades of work, dozens of trials) and narrow (most trials have been small, and the landmark ones failed their primary endpoints). Notable threads:

• Cardioprotection. The RED-CABG and MC-1 trials in the 1990s did not demonstrate the hypothesized reduction in perioperative cardiac events.
• Chronic lymphocytic leukemia. Phase 1/2 work from Campàs and colleagues showed activity but was not advanced to late-stage trials.
• Metabolic syndrome and diabetes. Small human studies have documented acute effects on insulin sensitivity consistent with the rodent data.

No AICAR or acadesine product has ever been approved by the FDA or EMA.

Practical Considerations

AICAR is poorly orally bioavailable; research protocols use intravenous or subcutaneous administration. Acadesine has better oral bioavailability and is the form that advanced through clinical trials. In community protocols the dose, duration, and route are highly inconsistent across sources — a reflection of the absence of any validated human use case.

Regulatory and Anti-Doping Status

AICAR is on the World Anti-Doping Agency (WADA) prohibited list at all times, classified under S4.4 (metabolic modulators). Cyclists and endurance athletes have tested positive for it, and a dedicated urinary detection assay was developed by WADA-accredited labs in the early 2010s. Any competitive athlete using AICAR is subject to sanction.

In the U.S., AICAR is not an approved drug, not a legal dietary supplement, and not a scheduled substance — it occupies a gray area as a research chemical. Purity and identity from research-chemical suppliers are not guaranteed.

The Bottom Line

AICAR is a legitimate pharmacological tool for studying AMPK and an interesting — but clinically unproven — exercise mimetic. Its animal-model results are striking; its human efficacy and long-term safety data are thin. For most readers it is primarily of research interest. Athletes should treat it as straightforwardly doping-banned with established detection methods.